Arcturus Therapeutics Plans 12-Week Phase 2 Cystic Fibrosis Trial After Positive Safety Data
Arcturus Therapeutics completed three 28-day inhaled mRNA cohorts for cystic fibrosis that were well-tolerated and showed early biological signals. The company is preparing a 12-week Phase 2 study with tightened eligibility criteria and expanded enrollment into Europe and the Middle East.